Last reviewed · How we verify
rAd5
At a glance
| Generic name | rAd5 |
|---|---|
| Sponsor | HIV Vaccine Trials Network |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan
- Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray (PHASE1, PHASE2)
- Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults (PHASE1)
- Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men (PHASE2)
- Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults (PHASE1)
- Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults (PHASE1)
- Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins (PHASE1)
- Antigenic Competition in HIV Preventive Vaccines (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rAd5 CI brief — competitive landscape report
- rAd5 updates RSS · CI watch RSS
- HIV Vaccine Trials Network portfolio CI